Cryptococcal meningitis is a dreadful opportunistic fungal infection amongst human immunodeficiency virus (HIV)-infected patients. One complication in the management of the disease is the possible infection of a patient by two or more different strains of Cryptococcus neoformans. This study investigated the intra-individual genetic diversity and antifungal susceptibility of C. neoformans isolates from Yaound e (Cameroon) HIV-infected patients with cryptococcal meningitis. Twenty-five clinical isolates were obtained during a prospective study. Five colonies were randomly collected from each initial sample. The 150 isolates obtained (125 colonies and 25 initial samples) were submitted to serotyping by multiplex PCR. Genotyping analyses were achieved using RFLP, and minisatellite-and microsatellite-length polymorphism. The antifungal susceptibility testing was carried out using a Sensititre YeastOne kit. Seven antifungals were tested: itraconazole, fluconazole, amphotericin B, ketoconazole, 5-fluorocytosine, posaconazole and voriconazole. The 150 isolates were identified as C. neoformans serotype A and genotype VNI. The microsatellite and minisatellite sequence analyses generated 15 genotypes. Six out of 25 (24 %) patients were found to be infected by two different genotypes. Antifungal susceptibility showed several profiles: posaconazole (0.015-0.25 µg ml À1 ), amphotericin B (0.06-1 µg ml À1 ), fluconazole (0.5-16 µg ml À1 ), itraconazole (0.008-0.12 µg ml À1 ), ketoconazole (0.008-0.12 µg ml À1 ), 5-fluorocytosine (0.25-16 µg ml À1 ) and voriconazole (0.008-0.12 µg ml À1 ). It was noted that isolates from the same patient might present different susceptibility profiles to an antifungal drug with differences of more than four dilutions. The results achieved highlighted the possible presence of isolates with different genotypes in a patient with dissimilar antifungal susceptibility profiles during a single episode of cryptococcal meningitis.
INTRODUCTION
Cryptococcus neoformans is a human opportunistic fungal pathogen causing severe disseminated meningoencephalitis, mostly in immunocompromised patients (Desnos-Ollivier et al., 2015) . The incidence of cryptococcal meningitis has increased since the advent of human immunodeficiency virus (HIV) infection (Jain et al., 2005; Casadevall, 2010) .
The mortality rate associated with the disease is considerable, especially in low-income communities where highly active antiretroviral therapy (HAART) is scarce (Lahuerta et al., 2013) . There has been an increase in the disease's incidence, with more than one million cases per annum and approximately 625 000 fatalities (Kronstad et al., 2011; UNAIDS, 2013) . The global incidence varies from 0.04 to 12 % and accounts for 13-40 % of the annual death rate among HIV-infected patients in areas of sub-Saharan Africa (Park et al., 2009) . The fungal agent involved in the disease is the C. neoformans/Cryptococcus gattii species complex, belonging to the phylum Basidiomycota and subdivided into seven haploid and four hybrid genotypes (Trilles et al., 2008; Meyer et al., 2009; Cogliati et al., 2013; Hagen et al., 2015) . C. neoformans var. grubii is represented by genotype AFLP1/VNI and the two minor genotypes AFLP1A/VNII (genotype VNB) and AFLP1B/VNII; C. neoformans var. neoformans is represented by genotype AFLP2/VNIV, while the hybrid between both varieties falls into genotype AFLP3/ VNIII. C. gattii can be separated into five genotypes, with genotypes AFLP4/VGI, AFLP6/VGII and AFLP10/VGIV corresponding to serotype B isolates, while genotypes AFLP5/VGIII and AFLP7/VGIV represent serotype C isolates. Recently, interspecies hybrids between C. gattii and C. neoformans were described, with the hybrid C. neoformans var. neoformans AFLP2/VNIV Â C. gattii AFLP4/VGI (serotype BD, genotype AFLP8), C. neoformans var. grubii AFLP1/VNI Â C. gattii AFLP4/VGI (serotype AB, genotype AFLP9) and C. neoformans var. grubii AFLP1/VNI Â C. gattii AFLP6/VGII (serotype AB, genotype AFLP11) (Meyer et al., 2009; Trilles et al., 2012; Cogliati et al., 2013; Kaocharoen et al., 2013; Hagen et al., 2015) . These major molecular types have subsequently been confirmed using RFLP analysis of the orotidine monophosphate pyrophosphorylase (URA5) or phospholipase B (PLB1) genes, amplified fragment-length polymorphism (AFLP) and multi-locus sequence typing (MLST) analysis. Differences in epidemiology, ecology and genetics have recently led to the taxonomic revision of the C. gattii/C. neoformans species complex (Hagen et al., 2015) . C. neoformans isolates with genotype AFLP1/VNI are globally predominant, except in Australia where C. gattii genotype AFLP4/VGI seems to be more common (Cogliati, 2013) . Information about molecular types in the central African region is scarce, however, especially in Cameroon. The molecular type VNI has been described recently in Cameroon (Bertout et al., 2013) . Moreover, it has been hypothesized that a given patient could be infected by more than one strain during an episode of the disease (Desnos-Ollivier et al., 2010 Illnait-Zaragozí et al., 2010b) . It was also observed that colonies from the same patient may present genetic variabilities (Bertout et al., 2013) . Ito-Kuwa et al. (2007) developed a genetic approach for the identification of C. neoformans serotypes by amplification of laccase and capsular genes in a single multiplex PCR. Multiple molecular-typing methods have been described to study the epidemiology of the C. neoformans species complex. The most commonly used approaches to date involve AFLP, PCR fingerprinting and PCR-RFLP (Meyer et al., 2009; Illnait-Zaragozí et al., 2010b; Hagen et al., 2012) . PCR fingerprinting and PCR-RFLP have proven useful in discriminating between the different serotypes and mating types, but have some limits for discrimination within specific C. neoformans species complex members. The MLST method has been applied on large sets of cryptococcal isolates covering the complete C. gattii/C. neoformans species complex (Hagen et al., 2012; Cogliati et al., 2013; Kaocharoen et al., 2013; Chen et al., 2015; Desnos-Ollivier et al., 2015) , but this technique is laborious, has a long turnaround time and is associated with significant costs. Microsatellites are increasingly popular moleculartyping targets, since they provide cost-effective genotyping with fast turnaround times. Like MLST data, microsatellitetyping data are transportable and exchangeable (Illnait-Zaragozí et al., 2010b) . This study describes the intra-individual genetic diversity of C. neoformans isolates from Yaound e HIV-infected patients assessed by using microsatellite length polymorphism analysis, and also evaluates the antifungal-susceptibility testing of these isolates with seven antifungal drugs.
METHODS
Patients. The patients were HIV-infected adults with clinical signs of meningitis admitted to the Yaound e Central Hospital. Ethical clearance was obtained from the Cameroonian National Ethical Committee (reference 117/CNE/DNM/08), and an informed consent signed by the patient or family member was obtained prior to each patient's enrolment as a participant. The inclusive criterion was a C. neoformans-positive culture from a cerebrospinal fluid (CSF) sample.
Isolates and colonies. The CSF was collected by lumbar puncture and subjected to India ink test, latex agglutination test (CRYPTO LA test; Fumouze Diagnostics) and cultured on Sabouraud dextrose agar without actidione (cycloheximide) for 2 to 14 days at 37 C. In the case of a positive culture, a urea test (bioMerieux) was carried out and culture purity was evaluated by subculturing on Niger (Guizotia abyssinica) seeds agar medium (Maslin et al., 2002) . Five colonies were randomly selected from Sabouraud dextrose agar plates and separately kept for further investigations.
DNA extraction. Total DNA extraction from fungal samples was performed as follows: fungal cells were disrupted (by glass beading at 6000 r.p.m. for 40 s, repeated four times) with a MagNA Lyser (Roche Diagnosis) in tubes containing 0.45 mm glass beads and 350 µl lysis buffer (2 % Triton X-100; 1 % SDS; 100 mM NaCl; 10 mM Tris-HCl, pH 8.0; 1 mM EDTA) (Promega). Then, DNA was purified using a NucleoSpin QuickPure kit (Macherey-Nagel), according to the manufacturer's manual. Genomic DNA was rapidly extracted by incubating previously disrupted cells for 15 min at 70 C in the presence of 25 µl proteinase K and 200 µl additional lysis buffer. DNA was thereafter suspended by adding 200 µl absolute ethanol, and centrifuged for 10 s at 12 100 g (MiniSpin Plus centrifuge; Eppendorf). The supernatant was transferred to a silica column and centrifuged for 1 min at 11 000 g. Adsorbed DNA was washed with a buffer containing 80 % ethanol and sodium chloride and dried by centrifugation (3 min, 11 000 g). DNA was finally eluted by centrifugation (1 min, 11 000 g) with 50 µl Tris-HCl, 5 mM, pH 8.5, heated at 70 C.
Serotyping by multiplex PCR. Serotype analysis was carried out by amplifying laccase and capsular genes, LAC1 and CAP64, respectively (Ito- Kuwa et al., 2007) . Specifically designed primers were used for this purpose. The single multiplex PCR was performed in a mix of 1Â buffer (Promega), 1.5 mM MgCl 2 (Promega), 0.2 mM dNTPs (Sigma Aldrich), 0.2 µM of each primer (Sigma Aldrich), 0.05 U Go Taq polymerase (Promega) µl 1 and 0.2 ng genomic DNA µl À1 . Amplification was carried out in a Primus 96 (Clemens) thermal cycler, and PCR conditions were as follows: initial denaturation at 94 C for 3 min; denaturation at 94 C for 30 s, annealing at 47 C for 60 s, extension 72 C for 1.5 min, repeated for 40 cycles; and a final extension at 72 C for 7 min (Ito-Kuwa et al., 2007) . PCR products were further separated by electrophoresis in 1.5 % agarose, Tris borate EDTA (TBE) gels.
RFLP-PCR of the URA5 gene. The URA5 gene was amplified using a specific pair of primers, URA5 and SJO1, as provided by Meyer et al. (2009) . The PCR mix comprised 1Â buffer (Promega), 1.5 mM MgCl 2 (Promega), 0.2 mM dNTPs (Sigma Aldrich), 0.2 µM each primer (Sigma Aldrich), 0.05 U Go Taq polymerase (Promega) µl À1 and 1 ng genomic DNA µl À1 . The amplification was carried out in a Techne TC-5000 (Bibby Scientific) thermal cycler, and PCR conditions were as follows: initial denaturation at 94 C for 2 min; 35 cycles of denaturation at 94 C for 45 s, annealing at 61 C for 60 s, extension at 72 C for 2 min; with a final extension at 72 C for 10 min. PCR products were further digested by Sau96I and HhaI restriction enzymes (Thermo Fisher Scientific) (Kaocharoen et al., 2013) and separated on 2 % agarose, TBE gels.
Microsatellite length polymorphism analysis. Microsatellites (GACA) 4 and (GTG) 5 , and M13 phage minisatellite, were used for fingerprint analysis. For the amplification of (GTG) 5 and M13, the PCR mix contained 1Â buffer (Promega), 1.5 mM MgCl 2 (Promega), 0.2 mM dNTPs (Sigma Aldrich), 0.4 µM primer (Sigma Aldrich), 0.05 U Go Taq polymerase (Promega) µl À1 and 1 ng genomic DNA µl À1 . Amplification was carried out in a Techne TC-5000 (Bibby Scientific) thermal cycler, and PCR conditions were as follows: initial denaturation at 94 C for 3 min; 40 cycles of denaturation at 94 C for 30 s, annealing at 50 C for 60 s, extension at 72 C for 1.5 min; with a final extension at 72 C for 6 min (Meyer et al., 2003; Bertout et al., 2013) .
The PCR mix for the (GACA) 4 sequence amplification consisted of 1Â buffer (Ozyme), 1.5 mM MgCl 2 (Ozyme), 0.2 mM dNTPs (Sigma Aldrich), 0.4 µM primer (Sigma Aldrich), 0.05 U Go Taq polymerase (Ozyme) µl À1 and 2 ng genomic DNA µl À1 . The amplification was carried out in a Primus 96 (Clemens) thermal cycler, and PCR conditions were as follows: initial denaturation at 94 C for 3 min; 40 cycles of denaturation at 94 C for 30 s, annealing at 40 C for 60 s, extension at 72 C for 1.5 min; with a final extension at 72 C for 7 min (Illnait-Zaragozí et al., 2010b) . Microsatellite amplified fragments were separated by electrophoresis using the high-resolution gel Poly(Nat) 6 % Wide Mini (Elchrom Scientific) for 105 min at 20 C in Tris acetate EDTA (TAE) buffer. Migration profiles were recorded using GeneSnap and GeneTools software (Syngene), and were then entered into a database created with GeneDirectory software (Syngene). Dendrograms were generated through this software, using a multi-experiment comparison tool and unweighted pair group with arithmetic mean (UPGMA algorithms.
Antifungal susceptibility testing. The Sensititre YeastOne antifungal susceptibility system (Thermo Scientific) was used according to the manufacturer's instructions as follows. A final micro-organism concentration of 1.5-8.10 3 c.f.u. ml 1 was recommended. The final inoculum in the broth was transferred onto YeastOne plates within 15 min. Twenty microlitres of yeast suspension were transferred into 11 ml Yea-stOne inoculum broth. Plates containing serial twofold dilutions of antifungal agents across 11 to 12 dilutions were inoculated using the prepared inoculum and incubated (35 C, 72 h). Each test consisted of a 96-well microplate, which contained dried serial dilutions of seven antifungal agents: posaconazole (0.008-8 µg ml À1 ), amphotericin B (0.008-16 µg ml À1 ), fluconazole (0.125-256 µg ml À1 ), itraconazole (0.008-16 µg ml À1 ), ketoconazole (0.008-16 µg ml À1 ), 5-fluorocytosine (flucytosine) (0.03-64 µg ml À1 ) and voriconazole (0.008-16 µg ml À1 ), in individual wells. The wells also contained a colorimetric indicator, which improves the end-point readability according to a colour change from blue to purple. The MIC was defined as the lowest concentration of an antifungal agent that substantially inhibited growth of the organism as detected by colour change. For experimental quality control, MIC data for two quality control reference strains, Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258, were evaluated each time that a set of isolates was tested. Each test was performed in triplicate.
RESULTS
The 25 patients included in the study were HIV-positive adults with a mean age of 38.9 ± 10.8 years, and the extremes were 25 and 74 years. Their CSF was culture positive for C. neoformans, confirmed by urea test and phenol oxidase activity on Niger seeds agar medium. Random isolation of five colonies from each initial culture provided 125 colonies from the 25 initial samples.
Serotype analyses of the 150 isolates (125 colonies and 25 initial samples) identified all the isolates as C. neoformans, serotype A. The URA5-RFLP yielded a profile similar to the C. neoformans genotype AFLP1/VNI reference strain for all tested isolates. Microsatellite-length polymorphism of microsatellites (GACA) 4 and (GTG) 5 and the M13 phage minisatellite generated individual genetic diversity. Microsatellite and minisatellite sequence analysis by the UPGMA method allowed the generation of 15 genotypes at 95 % similarity to the 150 isolates ( Fig. 1) . Analysis of the dendrogram also showed that a patient can be infected by two different strains, and the percentage of mixed infections was 24 (6/25 patients). Clones 1 and 3 from patient CM003 were found in the same clade, while being different from clones 2, 4 and 5 of the same patient. Among patients' CM020 and CM021 isolates were clone 1 belonging to genetic groups different from other clones.
Antifungal susceptibility testing
MICs of the 150 tested isolates are summarized in Table 1 . Fig. 2 provides the percentages of isolates at different concentrations of each antifungal drug tested. Differences in the MICs of isolates from a particular patient varied from 1 to 4 dilutions. Since the Clinical and Laboratory Standards Institute (CLSI) has not published MIC breakpoints for the antifungal susceptibility of C. neoformans, the published epidemiological cut-off values (ECVs) were used (Pfaller et al., 2011; Espinel-Ingroff et al., 2012a, b) to determine isolates with reduced susceptibility. One isolate (clone 3 from patient CM003) exhibited a reduced susceptibility to fluconazole (MIC=16 µg ml À1 ), while another isolate (clone 5 from patient CM005) revealed reduced susceptibility to 5fluorocytosine (MIC=16 µg ml À1 ). There was no relationship between genotypes and antifungal susceptibility. For example, the clones and initial sample of isolate CM001 possessed different antifungal susceptibilities while being grouped in the same clade (Table 2) . Fig. 1 . Dendrogram generated by UPGMA analysis of (GACA) 4 , (GTG) 5 and M13 phage. Molecular types are defined at 95 % similarity. The dendrogram was generated from the 150 isolates of C. neoformans formerly identified and serotyped, and
DISCUSSION
The 150 tested isolates were found to be C. neoformans serotype A, which reflected previous findings by Bertout et al. (2013) in a study of 114 isolates obtained from 19 HIV-positive patients at the Yaound e Central Hospital. This suggests that serotype A might be the principal serotype responsible for cryptococcal meningitis among Yaound e HIV-infected patients. Previous investigations showed that C. neoformans serotype A is widespread, especially amongst HIV-infected patients in the sub-Saharan African region (Cogliati, 2013) . The serotyping of C. neoformans has long been studied by latex agglutination tests (CryptoCheck; Iatron Laboratories) and cultured on canavanine glycine bromothymol blue medium (Carvalho et al., 2007; Ito-Kuwa et al., 2007) . However, the discovery of C. neoformans non-capsulated mutants (O'Meara et al., 2013) was associated with the stoppage of production of the CryptoCheck kit (Ito-Kuwa et al., 2007) and instigated the search for new approaches to discriminate C. neoformans serotypes. URA5-RFLP analysis provided results that are in agreement with previous findings (Cogliati, 2013; Cogliati et al., 2013) . Microsatellite-length polymorphisms of (GACA) 4 and (GTG) 5 microsatellite DNA, and M13 phage minisatellite DNA, grouped the 150 isolates into 15 major molecular types. Sixteen genotypes were obtained by Cogliati et al. (2013) when typ-ing53 Italian C. neoformans var. grubii serotype A. Microsatellite analysis [(CT)n, (TG)n, (TA)n, (CTA)n, (TCT)n, (CCA)n, (TTAT)n, (ATCC)n and (TATT)n] of 19 Cuban C. neoformans var. grubii serotype A isolates provided 14 molecular types (Illnait-Zaragozí et al., 2010b) . In the present study, 24 % (6/25) of patients were infected by allowed identification of genotypes named 1 to 15. *, isolate with reduced susceptibility to 5-fluorocytosine, CM003 clone 3 (MIC=16 µg ml À1 ); †, isolate with reduced susceptibility to fluconazole, CM005 clone 5 (MIC=16 µg ml À1 ). †For patients for whom the between-strain differences in antifungal susceptibility were of three dilutions or more, the MIC interval is shown in bold.
two different isolates. Although the results obtained have been variable, most authors have suggested that persistence or recurrence of the infection might be caused by relapse rather than reinfection and/or micro-evolution of the original isolate (Jain et al., 2005; Litvintseva et al., 2005) . A multi-strain infection was rarely considered until a recent Fig. 2 . Percentages of isolates at each dilution of antifungals. The vertical dashed line defines the ECVs as previously published for each antifungal at 72 h of incubation. Posaconazole (0.25 µg ml À1 ), amphotericin (1 µg ml À1 ), fluconazole (8 µg ml À1 ), itraconazole (0.25 µg ml À1 ), 5-fluorocytosine (8 µg ml À1 ), voriconazole (0.12 µg ml À1 ). There is no published value for the ECV of ketoconazole on C. neoformans (Pfaller et al., 2011; Espinel-Ingroff et al., 2012a, b) . *CM0X is the isolate number, CM0X-1 to CM0X-5 correspond to clones, and CM0X-0 is the initial sample. †Numbers correspond to various clades obtained after drawing the dendrogram from microsatellite analysis. study reported a high frequency of mixed infections in 20 % of patients with cryptococcal disease and hypothesized that multiple strains could be exogenously acquired from the environment, either simultaneously or sequentially (Desnos-Ollivieret al., 2010) . Morphologically similar colonies might have different genotypic backgrounds, as we have shown in the present work and also in previous publications (Desnos-Ollivier 2015) . Another speculation is that genetic variations in an initial strain allow for a better adaptation within the host organism (Illnait-Zaragozí et al., 2010b) . This process may allow the fungal population to change and escape eradication by the immune system, and thus cause chronic infections as suggested by Jain et al. (2005) . One interesting point is that there was no initial sample presenting mixed-microsatellite genotypes as we worked at 95 % similarities. Worth nothing is the high sensitivity of microsatellite analyses (Illnait-Zaragozi et al., 2010a) . The point to consider may be the potential presence of a predominant strain (genotype), which thereby masks other minor genotypes.
The antifungal susceptibility of isolates showed significant variability between isolates from the same patient. The CLSI has not published clinical breakpoints of antifungals for C. neoformans. However, some authors have published the susceptibility of C. neoformans isolates with breakpoints as follows: fluconazole (susceptible 8 g ml À1 ; susceptible dose-dependent 16-32 g ml À1 and resistant !64 g ml À1 ), 5fluorocytosine (susceptible 4 g ml À1 , intermediate 8-16 g ml À1 and resistant !32 g ml À1 ); amphotericin B, (susceptible 1 µg ml À1 , resistant >1 µg ml À1 ) (Mdodo et al., 2011; Bertout et al., 2012; Trilles et al., 2012) . Elsewhere, ECVs have been proposed to discriminate wild-type strains from mutants with reduced susceptibility to some antifungals (Pfaller et al., 2011; Espinel-Ingroff et al., 2012a) . Since the published ECV for fluconazole on C. neoformans is 8 µg ml À1 (Pfaller et al., 2011; Espinel-Ingroff et al., 2012a) , one isolate presented reduced susceptibility with a MIC of 16 µg ml À1 . C. neoformans isolates with reduced susceptibility to fluconazole have been published (Mdodo et al., 2011; Pfaller et al., 2011) . Moreover, it has been demonstrated that patients with a fluconazole MIC 8 µg ml À1 for their C. neoformans isolates respond better to antifungal treatment than those with isolates exhibiting a fluconazole MIC !16 µg ml À1 (Aller et al., 2000) . Nonetheless, recent recommendations for the treatment of cryptococcal meningitis in areas where amphotericin B as induction treatment is unavailable consist of high doses of fluconazole at 1200 mg daily for 2 weeks (WHO, 2011) . 5-Fluorocytosine is known to be linked with high levels of resistance development (Thompson et al., 2009 ). We observed one isolate with reduced susceptibility to that molecule, and this result is in accordance with previous findings (Thompson et al., 2009 ). Furthermore, it was observed that isolates from the same patient may express differences in their susceptibility to a given antifungal. Illnait-Zaragozi et al. (2010a) obtained differences in MICs between strains isolated during recurrent episodes of cryptococcal meningitis. The findings we obtained suggest that the patient was infected by different strains or that the initial strain underwent genetic microevolution leading to reduction of susceptibility to antifungal drugs (Illnait-Zaragozi et al., 2010a) .
Conclusion
The monitoring of cryptococcal meningitis among HIVinfected patients is a permanent query that guides the flow of research on the fungal agents responsible, members of the C. neoformans/C. gattii species complex. The present work has highlighted the possibility of isolates with different genotypes infecting a patient during one episode of the disease, associated with differences in the antifungal susceptibility of those isolates. Further investigations should be carried out to better understand whether the observed genetic diversity is due to infection by multiple isolates or to micro-evolutions that might occur in an original isolate.
